+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Duchenne Muscular Dystrophy - Pipeline Review, H2 2020

  • ID: 5146893
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 413 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AAVogen Inc
  • Bioleaders Corp
  • Dystrogen Therapeutics SA
  • InnoBioscience LLC
  • Nippon Shinyaku Co Ltd
  • ReveraGen BioPharma Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2020, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 5, 14, 11, 1, 59, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 12 and 2 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AAVogen Inc
  • Bioleaders Corp
  • Dystrogen Therapeutics SA
  • InnoBioscience LLC
  • Nippon Shinyaku Co Ltd
  • ReveraGen BioPharma Inc
  • MORE
Introduction
  • Duchenne Muscular Dystrophy - Overview
  • Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment

Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development

Duchenne Muscular Dystrophy - Drug Profiles

Duchenne Muscular Dystrophy - Dormant Projects
  • Duchenne Muscular Dystrophy - Discontinued Products
  • Duchenne Muscular Dystrophy - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Duchenne Muscular Dystrophy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, H2 2020
  • Duchenne Muscular Dystrophy - Pipeline by AAVogen Inc, H2 2020
  • Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H2 2020
  • Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, H2 2020
  • Duchenne Muscular Dystrophy - Pipeline by American CryoStem Corp, H2 2020
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2020
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..3), H2 2020
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..4), H2 2020
  • Duchenne Muscular Dystrophy - Discontinued Products, H2 2020
  • Duchenne Muscular Dystrophy - Discontinued Products, H2 2020 (Contd..1), H2 2020
List of Figures
  • Number of Products under Development for Duchenne Muscular Dystrophy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • 4D Molecular Therapeutics Inc
  • AAVogen Inc
  • Akashi Therapeutics Inc
  • Alpha Anomeric
  • American CryoStem Corp
  • Anagenesis Biotechnologies SAS
  • Antisense Therapeutics Ltd
  • Armgo Pharma Inc
  • Audentes Therapeutics Inc
  • AUM LifeTech Inc
  • Avidity Biosciences Inc
  • Axolo Pharma Inc
  • Biogen Inc
  • BioIncept LLC
  • Bioleaders Corp
  • Biophytis SA
  • Capricor Therapeutics Inc
  • Catabasis Pharmaceuticals Inc
  • Consortium.AI
  • Constant Therapeutics LLC
  • CRISPR Therapeutics AG
  • Cumberland Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • DepYmed Inc
  • DMD Therapeutics Inc
  • DTx Pharma Inc
  • Dyne Therapeutics Inc
  • Dystrogen Therapeutics SA
  • Edgewise Therapeutics
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • Epirium Bio Inc
  • Evox Therapeutics Ltd
  • FibroGen Inc
  • FibroGenesis LLC
  • Fulcrum Therapeutics Inc
  • Galapagos NV
  • GlaxoSmithKline Plc
  • InnoBioscience LLC
  • Italfarmaco SpA
  • Ixchel Pharma LLC
  • Keros Therapeutics Inc
  • LambdaGen Therapeutics
  • Milo Biotechnology LLC
  • Mitobridge Inc
  • Mitochon Pharmaceuticals Inc
  • MyoGene Bio LLC
  • Myos Inc
  • Myosana Therapeutics Inc
  • MyoTherix Inc
  • Nippon Shinyaku Co Ltd
  • OliPass Corporation
  • Oncotelic Inc
  • Pepgen Ltd
  • PeptiDream Inc
  • Pfizer Inc
  • PhaseBio Pharmaceuticals Inc
  • Pliant Therapeutics Inc
  • Progenitor Therapeutics Ltd
  • Prothelia Inc
  • PTC Therapeutics Inc
  • PYCTX Ltd
  • RASRx LLC
  • ReveraGen BioPharma Inc
  • Ridgeline Therapeutics LLC
  • Santhera Pharmaceuticals Holding AG
  • Sarcomed AB
  • Sarepta Therapeutics Inc
  • Solid Biosciences Inc
  • SOM Biotech SL
  • Stealth BioTherapeutics Corp
  • SteroTherapeutics LLC
  • Sutura Therapeutics Ltd
  • Taiho Pharmaceutical Co Ltd
  • Teijin Pharma Ltd
  • Tivorsan Pharmaceuticals Inc
  • Tolerion Inc
  • UGISense AG
  • Vertex Pharmaceuticals Inc
  • Vita Therapeutics Inc
  • Zata Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll